Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Cyteir: Stopping shape-shifters

Cyteir targets DNA repair enzyme critical for chronic lymphocytic leukemias

Cyteir Therapeutics Inc. is trying to curb the growth of chronic lymphocytic leukemia by blocking the repair of DNA damage. The company's small molecule hits a critical step in a DNA repair pathway that is overactive in about 40% of CLL patients.

DNA repair involves a series of enzymatic cuts and stitches to DNA molecules that become frayed as a result of mutation, radiation or chemically induced damage.

Many tumors spontaneously undergo rapid

Read the full 712 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers